Skip to content
DataLookout
Menu

NCT06512389

Evaluating Cannabidiol as a Novel Anticraving Medication for Alcohol Use Disorder

StatusActive, Not Recruiting
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Study completion pushed from Sep 30, 2026 to Jan 31, 2027
  2. Notable Eligibility criteria expanded, about 24 words Show 5 more changesShow less
    • Enrollment closed, study ongoing
    • Primary completion date changed from estimate of Jun 30, 2026 to Aug 20, 2026
    • Study completion pushed from Jun 30, 2026 to Sep 30, 2026
    • Secondary endpoints: details revised at 1 of 6 entries
    • Site details revised
  3. Minor Primary and study completion dates: Dec 31, 2026 to Jun 30, 2026v3
  4. Minor Start date changed from estimate of Jul 31, 2024 to Aug 16, 2024
    • Secondary endpoints: details revised at 2 of 6 entries
    v2
  5. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Total number of drinks administered during the alcohol-self administration session
Timeframe: 2 hours
Peak breath alcohol concentration during the alcohol-self administration session
Timeframe: 2 hours
Craving at baseline as measured by the Alcohol Urge Questionnaire during the alcohol self-administration session.
Timeframe: Baseline
Craving following the priming dose of alcohol as measured by the Alcohol Urge Questionnaire during the alcohol self-administration session.
Timeframe: 20 min after priming dose

Secondary (6)

Subjective effects of alcohol during the alcohol self-administration session as measured by the Drug Effects Questionnaire.
Subjective effects of alcohol during the alcohol self-administration session as measured by the Brief Biphasic Alcohol Effects Scale
Safety and tolerability of CBD
Differences in alcohol consumption (measured by the Timeline Follow Back method) outside of the lab during treatment with CBD vs. placebo
Differences in alcohol craving (measured by Penn Alcohol Craving Scale) outside of the lab during treatment with CBD vs. placebo
Show 1 moreShow less
Differences in self-reported anxiety (measured by modified Generalized Anxiety Disorder-7) outside of the lab during treatment with CBD vs. placebo

Arms and interventions

CannabidiolExperimental

10-day supply of 600 mg of CBD, taken orally twice daily

PlaceboPlacebo comparator

10-day supply of 600 mg of placebo, taken orally twice daily

Drugs: Oral solution

Sites

1 site in 1 country

  • Centre for Addiction and Mental HealthToronto, Ontario, Canada